Last updated on April 24, 2014 at 17:35 EDT

Medicago holds official ribbon cutting ceremony for its U.S. plant-based vaccine facility

November 10, 2011

RALEIGH, North Carolina and QUEBEC CITY, Quebec, Nov. 10, 2011 /PRNewswire/ -
Medicago U.S.A. Inc., a wholly owned subsidiary of Medicago Inc. (TSX:
MDG), a biotechnology company focused on developing highly effective
and affordable vaccines based on proprietary manufacturing technologies
and Virus-Like Particles (VLPs), today announced that company
executives, along with North Carolina Governor Beverly Perdue, U.S.
Senator Richard Burr and Congressman David Price, are holding an
official ribbon cutting ceremony on Monday, November 14(th) at 11am for its U.S. plant-based vaccine facility in Research Triangle
Park, North Carolina. The Company initially announced on September 13,
2011 that it commenced operations at this 97,000-square-foot vaccine

    Members of the media are invited to attend the officialribbon

        When:     Monday, November 14th at 11:00am

        Where:    7 Triangle Drive, Research Triangle Park, NC 27709

With this ribbon cutting ceremony, Medicago U.S.A. will officially open
its state-of-the-art vaccine facility in Research Triangle Park (RTP),
North Carolina. This VLP plant-based vaccine facility includes a fully
automated greenhouse and a state of the art extraction and purification
unit. The facility is targeted to produce 10 million doses of pandemic
influenza vaccine per month. On an annual basis, the facility will have
the production capacity of 40 million doses of seasonal Influenza
vaccine or 120 million doses of pandemic influenza vaccine.

About Medicago USA – DARPA Agreement
Medicago previously signed a US$21M Technology Investment Agreement with
the Defense Advanced Research Projects Agency (DARPA) to develop a
97,000-square-foot vaccine facility in Research Triangle Park (RTP),
North Carolina. This state of-the-art facility is a large,
cost-effective and scaled-up facility for Medicago’s VLP plant-based
vaccine technology ultimately for the delivery of current good manufacturing practice (cGMP)-grade vaccine. Medicago intends to demonstrate its capacity to
produce 10 million doses/month of influenza vaccines with the potential
for further expansion in the future. This DARPA project is part of the
Blue Angel influenza vaccine rapid response demonstration project which
seeks to identify new ways to produce large amounts of high quality
vaccine grade protein in less than 3 months in response to emerging and
novel biologic threats.

About Medicago’s Clinical Program
The Company reported positive phase II results for its clinical trial
with its H5N1 avian influenza vaccine in June 2011. The vaccine was
found to be safe, well tolerated and also induced a solid immune
response which is among the most effective of the industry.  The
Company also recently reported positive U.S. phase I results in its
clinical trial with its H1N1 / seasonal influenza vaccine candidate.
All tested doses were found safe and well-tolerated. A single dose of 5
mg met the 3 CHMP (The Committee for Medicinal Products for Human Use)
immunogenicity criteria. This phase I trial is expected to lead to
Medicago’s U.S. phase IIa trial for its seasonal trivalent vaccine with
the recommended H1N1, H3N2 and B influenza strains.

About Medicago
Medicago is committed to provide highly effective and competitive
vaccines based on proprietary Virus-Like Particle (VLP) and
manufacturing technologies. Medicago is developing VLP vaccines to
protect against H5N1 pandemic influenza, using a transient expression
system which produces recombinant vaccine antigens in non-transgenic
plants. This technology has potential to offer advantages of speed and
cost over competitive technologies. It could deliver a vaccine for
testing in about a month after the identification and reception of
genetic sequences from a pandemic strain. This production time frame
has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.

Forward Looking Statements

This news release includes certain forward-looking statements that are
based upon current expectations, which involve risks and uncertainties
associated with Medicago’s business and the environment in which the
business operates. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions “anticipate”, “believe”,
“plan”, “estimate”, “expect”, “intend”, and similar expressions to the
extent they relate to Medicago or its management. The forward-looking
statements are not historical facts, but reflect Medicago’s current
expectations regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results or events to differ materially from current
expectations, including the matters discussed under “Risks Factors and
Uncertainties” in Medicago’s Annual Information Form filed on March 31,
2011 with the regulatory authorities. Medicago assumes no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those reflected in the forward-looking

SOURCE Medicago Inc.

Source: PR Newswire